Efficacy of Vitamin E in Preventing Contrast-Induced Acute Kidney Injury Following Coronary Angiography
Phase 3
Completed
- Conditions
- Stable AnginaUnstable AnginaNon ST Segment Elevation Myocardial InfarctionPost MI
- Interventions
- Registration Number
- NCT02070679
- Lead Sponsor
- Urmia University of Medical Sciences
- Brief Summary
The purpose of this study is to evaluate the effect of vitamin E on preventing from incidence of contrast induced acute kidney injury (CI-AKI) in the patients who undergone coronary angiography.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 284
Inclusion Criteria
- All patients whon have either stable coronary artery disease (CAD) or recent acute coronary disease (ACS) and are scheduled for coronary angiography.
- Patients who have eGFR ≤60 ml/min/1.73 m2
Exclusion Criteria
- Allergy to contrast media
- Cardiogenic shock
- Pulmonary edema
- Overt cardiac failure or left ventricular ejection fraction ≤ 30%
- Acute kidney injury
- The history of receiving contrast media for any medical diagnostic or therapeutic procedures during previous 5 days
- The history of dialysis
- Being pregnant
- Having recent acute myocardial infarction
- Taking antioxidants and nephrotoxic drugs including NSAID and ACE-I on previous 2 days
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Vit-E Vitamin E 600 IU on 12 hours before angiography and 400 IU on 2 hours before angiography
- Primary Outcome Measures
Name Time Method The development of CI-AKI in group receiving vitamin E compared with placebo Within 72 hours after coronary angiography
- Secondary Outcome Measures
Name Time Method Changes in the serum level of Cr and the amount of eGFR Within 72 hours
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does vitamin E utilize to prevent contrast-induced acute kidney injury (CI-AKI)?
How does vitamin E compare to N-acetylcysteine in preventing CI-AKI post coronary angiography?
Which biomarkers are associated with susceptibility to CI-AKI in patients with angina or post-MI conditions?
What are the potential adverse events of high-dose vitamin E administration in cardiovascular patients?
Are there combination therapies involving vitamin E and renoprotective agents for preventing CI-AKI?
Trial Locations
- Locations (2)
Seyyed-al-Shohada Heart Center, UMSU
🇮🇷Urmia, West-Azerbaijan, Iran, Islamic Republic of
Taleghani Hospital, UMSU
🇮🇷Urmia, West-Azerbaijan, Iran, Islamic Republic of
Seyyed-al-Shohada Heart Center, UMSU🇮🇷Urmia, West-Azerbaijan, Iran, Islamic Republic of